This trial will use a precision based medicine approach in collaboration with the NantOmics GPS Cancer® platform for children with newly diagnosed High Grade Glioma (HGG). A specialized tumor board will recommend a treatment plan based on the results of the molecular profiling. All current FDA approved drugs will be considered for the treatment plan. Read the press release by clicking on the image.
The Pacific Pediatric Neuro-Oncology Consortium (PNOC) is a network of 18 children’s hospitals that conduct clinical trials of new therapies for children with brain tumors. Our goal is to improve outcomes by translating the latest findings in cancer biology into better treatments for these children.
Patients with brain tumors that cannot be treated with standard therapy, or that have recurred following standard therapy, are often eligible for clinical trials. Clinical trials provide access to promising new treatments that may not be available outside specialized centers.
At PNOC, our focus is personalized medicine – testing new therapies that are specific to the biology of each patient’s tumor to maximize their effectiveness. Our goal is to improve overall outcome for children with brain tumors.